Navigation Links
PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/11/2007

olecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies such as Pfizer, Celgene, CV Therapeutics and Schering-Plough.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...mab Program to be Discontinued and Headcount to be... its Portfolio Review; Zanolimumab Program to be ...r of Employees, COP...b A/S (OMX: GEN),announced today that it is discon... In addition, as a result of a portfolio review an...
(Date:10/8/2008)...gs Confirm Potency of Poly-ICR as Vaccine Adjuvant...nta Biopharmaceuticals,Corporation (TSX: NVN) toda... using its proprietary Toll-like Receptor 3 agonis...Vaccine Congress 2008 in Lyon, France.,Study resul...juvant,targeting the Toll-like Receptor 3 (TLR3) p...
(Date:10/7/2008)...ct. 7 /- Prometheus Laboratories Inc....ced findings from its,development of PROMETHEUS(R)... irritable bowel syndrome (IBS). The findings sugg...rticular biomarkers in blood samples,between IBS a...iomarkers,combined with a proprietary algorithm, ...
(Date:10/7/2008)...s, Oct. 7 /- The Texas Cardiac Arrhyt...r has been selected as one of,only a few sites in ...cal,trial for a new device to treat persistent atr..., training and research center specializing in hea...David,s Medical Center and,Texas Cardiovascular Co...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Park Dental Announces Separation From Its Administrative Service Provider 13335 1Park Dental Announces Separation From Its Administrative Service Provider 13335 2Park Dental Announces Separation From Its Administrative Service Provider 13335 3Highlands Acquisition Corp Receives Non Compliance Letter From Amex 13334 1Highlands Acquisition Corp Receives Non Compliance Letter From Amex 13334 2Pump It Up and Autism Society of America Launch Bounce for Autism 13331 1Pump It Up and Autism Society of America Launch Bounce for Autism 13331 2Pump It Up and Autism Society of America Launch Bounce for Autism 13331 3MSU research indicates testosterone could guard against eating disorders 13329 1MSU research indicates testosterone could guard against eating disorders 13329 2
...the CDC that none of its influenza vaccine (Fluvir...ted States for the current influenza season. In th...e anticipated American vaccine supply, medical off...gly alarmed about the scarcity of vaccine and the ...e seen if virulent new strains of flu or an abnorm...
...f rapid, easy-to-use diagnostic tests, many assays...ace to help clinicians assess dosage appropriatene...ence of drugs of abuse. Some of these products req...s are suitable for point of care use by medical pr..., Therapeutic drug monitoring measures the serum ...
Other Medicine Technology:Rapid Flu Tests May Prove Especially Helpful This Season 2Rapid Flu Tests May Prove Especially Helpful This Season 3Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse 2Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse 3Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse 4
(Date:10/10/2008)...t. 10 /PRNewswire/ -- A nationally recognized facu...ies for patients with breast,cancer in the multime...tegies: From Biomarkers to Treatment Selection" du...is challenging for practicing oncologists and othe...ate on the latest patient care,advances. This accr...
(Date:10/9/2008)...ACH, Fla., Oct. 9 /PRNewswire/ -- This may sound l...reality. Internationally,acclaimed anti-aging Doct...licensed to provide TA-65 to the public through hi...ida., This is a revolutionary technology that is ...our DNA. They are located at the ends of all the,c...
(Date:10/9/2008)...y Rewards and Educational Opportunities for Those ...PHILADELPHIA, Oct. 9 /PRNewswire/ -- In recognitio...Blue Cross (IBC) honors its more than,590 customer... with fun,healthy activities this week and celebr...., Fielding more than 4 million inquiries a year,...
(Date:10/9/2008)...s., Oct. 9 /PRNewswire/ -- Nature,s Way Holding Co...hwabe Pharmaceuticals, a leading,worldwide produce...,agreement to acquire all outstanding shares of En...he controlling shareholder of Enzymatic Therapy. T...vering their signatures and,provides for customary...
Breaking Medicine News(10 mins):Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2Health News:Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging 2Health News:Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging 3Health News:Independence Blue Cross Celebrates Customer Service Week 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 3
...se or survival for children and young adults with ...ancer Hospital at The University of Texas M. D. A...g leukemia patients over the past decade has shown...C), a measure of normal immune cells found on ever...
...boosted the potency of platinum-based cancer drugs... cell lines and to mice with tumors, scientists f...g a platinum chemotherapy agent and the diabetes d...e tumors as much as three times more effectively t...
...ect for countries that recently have made progress...t released on Monday by Save the Children, the Ne... the World's Mothers: Saving the Lives of Children... a mother and child in 60 developing countries whe...
...urnal of the American Medical Association, researc...of contracting lymphoma. The cancer of the immun...d to be 30 percent times higher in patients with h...denstroms macroglobulinemia, the risk of a hepatit...
Other Medicine News:Health News:Lymphocyte Count Found to Be a Predictor of Survival for Young Patients With Leukemia 2Health News:Diabetes Drug Dramatically Boosts Potency of Platinum Chemotherapy 2Health News:Diabetes Drug Dramatically Boosts Potency of Platinum Chemotherapy 3Health News:Family Planning Initiatives Central To Reducing Child Mortality in Developing Countries 2Health News:Hepatitis C Carries Another Risk-Cancer Of The Immune System 2
...medication, food, exercise, stress . . . Theyre al...health. Unfortunately, its difficult, and often ov...tion on a daily basis. Its even more difficult to ...formation to a care provider quickly so healthcare...
...es requires making decisions about insulin dosages... These decisions are guided by data from blood glu...the patterns that can be seen by you and your Heal...ganized and graphical formats. The FreeStyle CoPil...
...t Solid-State Three-Color Photocoagulator.,Retin...purchase over 3,000 Lumenis multi-color photocoagu...ractice, the Novus Varia integrates green, yellow,... single, compact system that supports your treatme...
...pe 14, 14A and 14C have been approved. The three r...modate the variations in the size of the individua... rings are designed to stabilize the capsule and h...e panel of U.S. ophthalmologists. For implatation...
Medicine Products: